The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 25, 2021

Filed:

Sep. 24, 2018
Applicant:

Purdue Research Foundation, West Lafayette, IN (US);

Inventors:

Ji-Xin Cheng, Newton, MA (US);

Mohamed Seleem, West Lafayette, IN (US);

Pu-Ting Dong, Boston, MA (US);

Jie Hui, Boston, MA (US);

Assignee:

Purdue Research Foundation, West Lafayette, IN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61N 5/06 (2006.01); C12N 13/00 (2006.01); A61K 31/546 (2006.01); A61K 31/7036 (2006.01); A61K 31/496 (2006.01); A61K 38/12 (2006.01); A61K 31/431 (2006.01); A61N 5/067 (2006.01);
U.S. Cl.
CPC ...
A61N 5/0624 (2013.01); A61K 31/431 (2013.01); A61K 31/496 (2013.01); A61K 31/546 (2013.01); A61K 31/7036 (2013.01); A61K 38/12 (2013.01); A61N 5/0603 (2013.01); C12N 13/00 (2013.01); A61N 5/0616 (2013.01); A61N 2005/0605 (2013.01); A61N 2005/0607 (2013.01); A61N 2005/067 (2013.01); A61N 2005/0663 (2013.01);
Abstract

Methicillin-resistant(MRSA) possesses array of strategies to evade antibiotics through mutational inactivation, hiding inside host immune cells or concealing inside the biofilm in a sessile form. We report a drug-free approach to eradicate MRSA through blue-light bleaching of staphyloxanthin (STX), an anti-oxidative carotenoid residing inside the cell membrane of. The photobleaching process, uncovered through a transient absorption imaging study and quantitated by mass spectrometry, decomposes STX and sensitizes MRSA to reactive oxygen species attack. Consequently, photobleaching using low-level blue light exhibits high-level synergy when combined with low-concentration of hydrogen peroxide. Antimicrobial effectiveness of this synergistic therapy is validated in MRSA culture, MRSA-infected macrophage cells, biofilm, and a mouse wound infection model. Collectively, these findings highlight broad applications of STX photobleaching for MRSA-infected diseases.


Find Patent Forward Citations

Loading…